Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution
Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Izidore S. Lossos(Sylvester Comprehensive Cancer Center), Erik L. Kimble(University of Washington), Jeremy Ramdial(The University of Texas MD Anderson Cancer Center), Macarena I. de la Fuente(Sylvester Comprehensive Cancer Center), Wei Zhao(University of Miami), Francisco Vega(The University of Texas MD Anderson Cancer Center), Isildinha M. Reis(University of Miami), Jennifer R. Chapman(University of Miami), Nicolas Gallastegui(The Ohio State University), Joseph D. Rosenblatt(Sylvester Comprehensive Cancer Center), Amrita Desai(Oregon Health & Science University)
Cited by 79
Related Papers
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
|Blood|2020|217
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
|Blood Advances|2021|146
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
|Transplantation and Cellular Therapy|2023|144